Analyst consensus rating
60 Degrees Pharmaceuticals Analyst Rating: Buy
SXTP is rated Buy by 1 analysts with a $3.70 target. As of 2026-08-23.
Direct answer
60 Degrees Pharmaceuticals's consensus rating is Buy.
1 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $3.70.
Forecast evidence checked August 23, 2026.
Get free 60 Degrees Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $1.13
- Average price target
- $3.70
- High price target
- $3.70
- Low price target
- $3.70
- Low target gap
- +227.4%
- Target upside
- +227.4%
- High target gap
- +227.4%
- Target range width
- 0%
- Consensus rating
- Buy
- Analysts
- 1
- Evidence date
- August 23, 2026
- Valid through
- August 30, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for 60 Degrees Pharmaceuticals?
60 Degrees Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $3.70.
How far are 60 Degrees Pharmaceuticals's low and high targets from the recorded price?
The low target implies +227.4%, while the high target implies +227.4%.
How many analysts are included in 60 Degrees Pharmaceuticals's consensus?
The verified consensus includes 1 analysts.
How is 60 Degrees Pharmaceuticals's target upside or downside calculated?
The average target of $3.70 is divided by the recorded price of $1.13, then one is subtracted to produce +227.4%. This does not guarantee a future return.
When was 60 Degrees Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-23. The dataset is valid through 2026-08-30.